Multidrug-resistant organisms in cystic fibrosis: Management and infection-control issues

Expert Review of Anti-Infective Therapy

Volumn 4, Issue 5, 2006, Pages 807-819

  Waters, Valerie ^a   Ratjen, Felix ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Cystric fibrosis; Infection control; Management; Multidrug resistant

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; AZATHIOPRINE; AZTREONAM; BETA LACTAM ANTIBIOTIC; CARBAPENEM; CATHELICIDIN; CEFTAZIDIME; CHLORAMPHENICOL; CIPROFLOXACIN; COLISTIN; COTRIMOXAZOLE; CYCLOSPORIN; DORIPENEM; DOXYCYCLINE; FOSFOMYCIN; FOSFOMYCIN CALCIUM; FOSFOMYCIN SODIUM; FOSFOMYCIN TROMETAMOL; GENTAMICIN; LEVOFLOXACIN; MEROPENEM; MONOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TEMOCILLIN; TIMENTIN; TOBRAMYCIN; TRIMETHOPRIM; UNINDEXED DRUG;

ACHROMOBACTER XYLOSOXIDANS; ACUTE KIDNEY FAILURE; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; BACTERIAL TRANSMISSION; BACTERIUM ISOLATE; BRONCHOSPASM; BURKHOLDERIA CEPACIA; CLINICAL TRIAL; COUGHING; CYSTIC FIBROSIS; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG POTENTIATION; DRUG TREATMENT FAILURE; GRAFT REJECTION; GRAM NEGATIVE INFECTION; HUMAN; INFECTION CONTROL; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MULTIDRUG RESISTANCE; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; PATHOGENICITY; PROGNOSIS; PSEUDOMONAS AERUGINOSA; REVIEW; STENOTROPHOMONAS MALTOPHILIA; THORAX PAIN;

ANTI-INFECTIVE AGENTS; CYSTIC FIBROSIS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; INFECTION CONTROL; RESPIRATORY TRACT INFECTIONS;

EID: 33845442495     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.4.5.807     Document Type: Review

References (148)

1. Ratjen F, Doting G. Cystic fibrosis. Lancet 361, 681-689 (2003).
2. Registry CFF. 2001 Annual Data Report to the Center Directors. Foundation, CF (Ed.) MD, USA (2002).
3. Burns JL, Gibson RL, McNamara S et al. Longitudinal assessment of Pseudomonas aeruginosa in young children with cystic fibrosis. J. Infect. Dis. 183(3), 444-452 (2001).
4. Pamukcu A, Bush A, Buchdahl R. Effects of Pseudomonas aeruginosa colonization on lung function and anthropometric variables in children with cystic fibrosis. Pediatr. Pulmonol. 19(1), 10-15 (1995).
5. Kosorok MR, Zeng L, West SE et al. Acceleration of lung disease in children with cystic fibrosis after Pseudomonas aeruginosa acquisition. Pediatr. Pulmonol. 32(4), 277-287 (2001).
6. Henry RL, Mellis CM, Petrovic L. Mucoid Pseudomona aeruginosa is a marker of poor survival in cystic fibrosis. Pediatr. Pulmonol. 12(3), 158-161 (1992).
7. Mahenthiralingam E, Campbell ME, Foster J, Lam JS, Speert DP. Random amplified polymorphic DNA typing of Pseudomonas aeruginosa isolates recovered from patients with cystic fibrosis. J. Clin. Microbiol. 34(5), 1129-1135 (1996).
8. Ciofu O, Giwercman B, Pedersen SS, Hoiby N. Development of antibiotic resistance in Pseudomonas aeruginosa during two decades of antipseudomonal treatment at the Danish CF Center. Apmis 102(9), 674-680 (1994).
9. Godfrey AJ, Bryan LE, Rabin HR. β-lactam-resistant Pseudomonas aeruginosa with modified penicillin-binding proteins emerging during cystic fibrosis treatment. Antimicrob. Agents Chemother. 19(5), 705-711 (1981).
10. Poole K. Aminoglycoside resistance in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 49(2), 479-87 (2005).
11. Saiman L, Mehar F, Niu WW et al. Antibiotic susceptibility of multiply resistant Pseudomonas aeruginosa isolated from patients with cystic fibrosis, including candidates for transplantation. Clin. Infect. Dis. 23(3), 532-537 (1996).
12. Cheng K, Smyth RL, Govan JR et al. Spread of β-lactam-resistant Pseudomonas aeruginosa in a cystic fibrosis clinic. Lancet, 348(9028), 639-642 (1996).
13. Panagea S, Winstanley C, Parsons YN et al. PCR-based detection of a cystic fibrosis epidemic strain of Pseudomonas aeruginosa. Mol. Diagn. 7(3-4), 195-200 (2003).
14. Scott FW, Pitt TL. Identification and characterization of transmissible Pseudomonas aeruginosa strains in cystic fibrosis patients in England and Wales. J. Med. Microbiol. 53(Pt 7), 609-615 (2004).
15. Nixon GM, Armstrong DS, Carzino R et al. Clinical outcome after early Pseudomonas aeruginosa infection in cystic fibrosis. J. Pediatr. 138(5), 699-704 (2001).
16. McCallum SJ, Corkill J, Gallagher M et al. Superinfection with a transmissible strain of Pseudomonas aeruginosa in adults with cystic fibrosis chronically colonised by P. aeruginosa. Lancet 358(9281), 558-560 (2001).
17. McCallum SJ, Gallagher MJ, Corkill JE et al. Spread of an epidemic Pseudomonas aeruginosa strain from a patient with cystic fibrosis (CF) to non-CF relatives. Thorax 57(6), 559-560 (2002).
18. Al-Aloul M, Crawley J, Winstanley C et al. Increased morbidity associated with chronic infection by an epidemic Pseudomonas aeruginosa strain in CF patients. Thorax 59(4), 334-336 (2004).
19. Al-Aloul M, Miller H, Stockton P, Ledson MJ, Walshaw MJ. Acute renal failure in CF patients chronically infected by the Liverpool epidemic Pseudomonas aeruginosa strain (LES). J. Cyst. Fibros. 4(3), 197-201 (2005).
20. Dobbin C, Maley M, Harkness J et al. The impact of pan-resistant bacterial pathogens on survival after lung transplantation in cystic fibrosis: results from a single large referral centre. J. Hosp. Infect. 56(4), 277-282 (2004).
21. Aaron SD, Vandemheen KL, Ferris W et al. Combination antibiotic susceptibility testing to treat exacerbations of cystic fibrosis associated with multiresistant bacteria: a randomized, double-blind, controlled clinical trial. Lancet 366(9484), 463-471 (2005).
22. Foweraker JE, Laughton CR, Brown DF, Bilton D. Phenotypic variability of Pseudomonas aeruginosa in sputa from patients with acute infective exacerbation of cystic fibrosis and its impact on the validity of antimicrobial susceptibility testing. J. Antimicrob. Chemother 55(6), 921-927 (2005).
23. Figueredo VM, Neu HC. Synergy of ciprofloxacin with fosfomycin in vitro against Pseudomonas isolates from patients with cystic fibrosis. J. Antimicrob. Chemother. 22(1), 41-50 (1988).
24. Forsgren A, Walder M. Antimicrobial activity of fosfomycin in vitro. J. Antimicrob. Chemother. 11 (5), 467-471 (1983).
25. Mirakhur A, Gallagher MJ, Ledson MJ, Hart CA, Walshaw MJ. Fosfomycin therapy for multiresistant Pseudomonas aeruginosa in cystic fibrosis. J. Cyst. Fibros. 2(1), 19-24 (2003).
26. Durupt S, Josserand RN, Sibille M, Durieu I. Acute, recurrent fosfomycin-induced liver toxicity in an adult patient with cystic fibrosis. Scand. J. Infect. Dis., 33(5), 391-392 (2001).
27. Beringer P. The clinical use of colistin in patients with cystic fibrosis. Curr. Opin. Pulm. Med. 7(6), 434-440 (2001).
28. Groisman EA, Kayser J, Soncini FC. Regulation of polymyxin resistance and adaptation to low-Mg2+ environments. J. Bacteriol. 179(22), 7040-7045 (1997).
29. Ledson MJ, Gallagher MJ, Cowperthwaite C, Convery RP, Walshaw MJ. Four years' experience of intravenous colomycin in an adult cystic fibrosis unit. Eur. Respir. J. 12(3), 592-594 (1998).
30. Ratjen F, Rietschel E, Kasel D et al. Pharmacokinetics of inhaled colistin in patients with cystic fibrosis. J. Antimicrob. Chemother. 57(2), 306-311 (2006).
31. Cunningham S, Prasad A, Collyer L et al. Bronchoconstriction following nebulised colistin in cystic fibrosis. Arch. Dis. Child. 84(5), 432-433 (2001).
32. Saiman L, Tabibi S, Starner TD et al. Cathelicidin peptides inhibit multiply antibiotic-resistant pathogens from patients with cystic fibrosis. Antimicrob. Agents Chemother. 45(10), 2838-2844 (2001).
33. Valerius NH, Koch C, Hoiby N. Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment. Lancet 338(8769), 725-726 (1991).
34. Ratjen F, Doring G, Nikolaizik WH. Effect of inhaled tobramycin on early Pseudomonas aeruginosa colonisation in patients with cystic fibrosis. Lancet 358(9286), 983-984 (2001).
35. Hoiby N, Frederiksen B, Pressler T. Eradication of early Pseudomonas aeruginosa infection. J. Cyst. Fibros. 4(Suppl. 2), S49-S54 (2005).
36. Burns JL, Van Dalfsen JM, Shawar RM et al. Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis. J. Infect. Dis. 179(5), 1190-1196 (1999).
37. Lipuma JJ. Update on the Burkholderia cepacia complex. Curr. Opin. Pulm. Med. 11(6), 528-533 (2005).
38. Vandamme P, Holmes B, Vancanneyt M et al. Occurrence of multiple genomovars of Burkholderia cepacia in cystic fibrosis patients and proposal of Burkholderia multivorans sp. nov. Int. J. Syst. Bacteriol. 47(4), 1188-1200 (1997).
39. Vermis K, Coenye T, LiPuma JJ et al. Proposal to accommodate Burkholderia cepacia genomovar VI as Burkholderia dolosa sp. nov. Int. J. Syst. Evol. Microbiol. 54(Pt 3), 689-691 (2004).
40. Hancock RE. Resistance mechanisms in Pseudomonas aeruginosa and other nonfermentative Gram-negative bacteria. Clin. Infect. Dis. 27(Suppl. 1), S93-S99 (1998).
41. Burns JL, Lien DM, Hedin LA. Isolation and characterization of dihydrofolate reductase from trimethoprim-susceptible and trimethoprim-resistant Pseudomonas cepacia. Antimicrob. Agents Chemother. 33(8), 1247-1251 (1989).
42. Desai M, Buhler T, Weller PH, Brown MR. Increasing resistance of planktonic and biofilm cultures of Burkholdria cepacia to ciprofloxacin and ceftazidime during exponential growth. J. Antimicrob. Chemother 42(2), 153-160 (1998).
43. Venturi V, Friscina A, Bertani I, Devescovi G, Aguilar C. Quorum sensing in the Burkholdria cepacia complex. Res. Microbiol. 155(4), 238-244 (2004).
44. Nalca Y, Jansch L, Bredenbruch F, Geffers R, Buer J, Haussler S. Quorum-sensing antagonistic activities of azithromycin in Pseudomonas aeruginosa PAO1: a global approach. Antimicrob. Agents Chemother. 50(5), 1680-1688 (2006).
45. Mahenthiralingam E, Simpson DA, Speert DR Identification and characterization of a novel DNA marker associated with epidemic Burkholderia cepacia strains recovered from patients with cystic fibrosis. J. Clin. Microbiol. 35(4), 808-816 (1997).
46. Goldstein R, Sun L, Jiang RZ et al. Structurally variant classes of pilus appendage fibers coexpressed from Burkholdria (Pseudomonas) cepacia. J. Bacteriol, 177(4), 1039-1052 (1995).
47. Sun L, Jiang RZ, Steinbach S et al. The emergence of a highly transmissible lineage of cbl+ Pseudomonas (Burkholdria) cepacia causing CF centre epidemics in North America and Britain. Nat. Med. 1(7), 661-666 (1995).
48. Mahenthiralingam E, Vandamme P, Campbell ME et al. Infection with Burkholdria cepacia complex genomovars in patients with cystic fibrosis: virulent transmissible strains of genomovar III can replace Burkholderia multivorans. Clin. Infect. Dis. 33(9), 1469-1475 (2001).
49. Isles A, Madusky I, Corey M et al. Pseudomonas cepacia infection in cystic fibrosis: an emerging problem. J. Pediatr. 104(2), 206-210 (1984).
50. Mahenthiralingam E, Urban TA, Goldberg JB. The multifarious, multireplicon Burkholdria cepacia complex. Nat. Rev. Microbiol 3(2), 144-156 (2005).
51. Reik R, Spilker T, Lipuma JJ. Distribution of Burkholdria cepacia complex species among isolates recovered from persons with or without cystic fibrosis. J. Clin. Microbiol. 43(6), 2926-2928 (2005).
52. LiPuma JJ, Spilker T, Coenye T, Gonzalez CF. An epidemic Burkholdria cepacia complex strain identified in soil. Lancet 359(9322), 2002-2003 (2002).
53. Chen JS, Witzmann KA, Spitker T, Fink RJ, LiPuma JJ. Endemicity and inter-city spread of Burkholdria cepacia genomovar III in cystic fibrosis. J. Pediatr. 139(5), 643-649 (2001).
54. Doring G, Jansen S, Noll H et al. Distribution and transmission of Pseudomonas aeruginosa and Burkholdria cepacia in a hospital ward. Pediatr. Pulmonol. 21(2), 90-100 (1996).
55. Campana S, Taccerti G, Ravenni N et al. Transmission of Burkholderia cepacia complex: evidence for new epidemic clones infecting cystic fibrosis patients in Italy. J. Clin. Microbiol. 43(10), 5136-5142 (2005).
56. Walsh NM, Casano AA, Manangan LP, Sinkowitz-Cochran RL, Jarvis WR. Risk factors for Burkholderia cepacia complex colonization and infection among patients with cystic fibrosis. J. Pediatr. 141(4), 512-517 (2002).
57. Speert DP, Henry D, Vandamme P, Corey M, Mahenthiralingam E. Epidemiology of Burkholderia cepacia complex in patients with cystic fibrosis, Canada. Emerg. Infect. Dis. 8(2), 181-187 (2002).
58. Johnson WM, Tyler SD, Rozee KR. Linkage analysis of geographic and clinical clusters in Psedomonas cepacia infections by multilocus enzyme electrophoresis and ribotyping. J. Clin. Microbiol. 32(4), 924-930 (1994).
59. Coenye T, LiPuma JJ. Population structure analysis of Burkholderia cepacia genomovar III: varying degrees of genetic recombination characterize major clonal complexes. Microbiology 149(Pt 1), 77-88 (2003).
60. Jones AM, Dodd ME, Govan JR et al. Burkholderia cenocepacia and Burkholderia multivorans: influence on survival in cystic fibrosis. Thorax 59(11), 948-951 (2004).
61. Courtney JM, Dunbar KE, McDowell A et al. Clinical outcome of Burkholderia cepacia complex infection in cystic fibrosis adults. J. Cyst. Fibros. 3(2), 93-98 (2004).
62. Johansen HK, Kovesi TA, Koch C et al. Pseudomonas aeruginosa and Burkholderia cepacia infection in cystic fibrosis patients treated in Toronto and Copenhagen. Pediatr. Pulmonol. 26(2), 89-96 (1998).
63. De Soyza A, Morris K, McDowell A et al. Prevalence and clonality of Burkholderia cepacia complex genomovars in UK patients with cystic fibrosis referred for lung transplantation. Thorax 59(6), 526-528 (2004).
64. Kalish LA, Waltz DA, Davey M et al. Impact of Burkholderia dolosa on lung function and survival in cystic fibrosis. Am. J. Respir. Crit. Care Med. 173(4), 421-425 (2006).
65. Bernhardt SA, Spilker T, Coffey T, LiPuma JJ. Burkholderia cepacia complex in cystic fibrosis: frequency of strain replacement during chronic infection. Clin. Infect. Dis. 37(6), 780-785 (2003).
66. Laing R TE, Corey M. Transient sputum culture of Burkholderia cepacia in cystic fibrosis patients: epidemiology and clinical implications. In: 7th Meeting of the International Burkholderia cepacia Working Group (Eds). TX, USA April 2002.
67. Aaron SD, Ferris W, Henry DA, Speert DP, Macdonald NE. Multiple combination bactericidal antibiotic testing for patients with cystic fibrosis infected with Burkholderia cepacia. Am. J. Respir Crit. Care Med 161(4 Pt 1), 1206-1212 (2000).
68. Taylor RF, Gaya H, Hodson ME. Temocillin and cystic fibrosis: outcome of intravenous administration in patients infected with Pseudomonas cepacia. J. Antimicrob. Chemother 29(3), 341-344 (1992).
69. Lekkas A, Gyi KM, Hodson ME. Temocillin in the treatment of Burkholderia cepacia infection in cystic fibrosis. J. Cyst. Fibros. 5(2), 121-124 (2006).
70. Traczewski MM, Brown SD. In vitro activity of doripenem against Pseudomonas aeruginosa and Burkholderia cepacia isolates from both cystic fibrosis and non-cystic fibrosis patients. Antimicrob. Agents Chemother 50(2), 819-821 (2006).
71. Chen Y, Garber E, Zhao Q et al. In vitro activity of doripenem. (S-4661) against multidrug-resistant Gram-negative bacilli isolated from patients with cystic fibrosis. Antimicrob. Agents Chemother 49(6), 2510-2511 (2005).
72. Chaparro C, Maurer J, Gutierrez C et al. Infection with Burkholderia cepacia in cystic fibrosis: outcome following lung transplantation. Am. J. Respir. Crit. Care Med 163(1), 43-48 (2001).
73. Etherington C, Peckham DG, Conway SP, Denton M. Burkholderia cepacia complex infection in adult patients with cystic fibrosis - is early eradication possible? J. Cyst. Fibros. 2(4), 220-221 (2003).
74. Gibson RL, Burns JL, Ramsey BW. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am. J. Respir. Crit. Care Med. 168(8), 918-951 (2003).
75. Valdezate S, Vindel A, Maiz L et al. Persistence and variability of Stenotrophomonas maltophilia in cystic fibrosis patients, Madrid, 1991-1998. Emerg. Infect. Dis. 7(1), 113-122 (2001).
76. Steinkamp G, Wiedemann B, Rietschel E et al. Prospective evaluation of emerging bacteria in cystic fibrosis. J. Cyst. Fibros. 4(1), 41-48 (2005).
77. Alonso A, Morales G, Escalante R et al. Overexpression of the multidrug efflux pump SmeDEF impairs Stenotrophomonas maltophilia physiology. J. Antimicrob. Chemother. 53(3), 432-434 (2004).
78. Karpati F, Malmborg AS, Alfredsson H, Hjelte L, Strandvik B. Bacterial colonisation with Xanthomonas maltophilia - a retrospective study in a cystic fibrosis patient population. Infection 22(4), 258-263 (1994).
79. Marchac V, Equi A, Le Bihan-Benjamin C, Hodson M, Bush A. Case-control study of Stenotrophomonas maltophilia acquisition in cystic fibrosis patients. Eur. Respir. J. 23(1), 98-102 (2004).
80. Graff GR, Burns JL. Factors affecting the incidence of Stenotrophomonas maltophilia isolation in cystic fibrosis. Chest 121(6), 1754-1760 (2002).
81. Talmaciu I, Varlotta L, Mortensen J, Schidlow DV. Risk factors for emergence of Stenotrophomonas maltophilia in cystic fibrosis. Pediatr. Pulmonol. 30(1), 10-15 (2000).
82. Manno G, Dalmastri C, Tabacchioni S et al. Epidemiology and clinical course of Burkholderia cepacia complex infections, particularly those caused by different Burkholderia cenocepacia strains, among patients attending an Italian Cystic Fibrosis Center. J. Clin. Microbiol. 42(4), 1491-1497 (2004).
83. Goss CH, Otto K, Aitken ML, Rubenfeld GD. Detecting Stenotrophomonas maltophilia does not reduce survival of patients with cystic fibrosis. Am. J. Respir. Crit. Care Med. 166(3), 356-361 (2002).
84. Goss CH, Mayer-Hamblett N, Aitken ML, Rubenfeld GD, Ramsey BW. Association between Stenotrophomonas maltophilia and lung function in cystic fibrosis. Thorax 59(11), 955-959 (2004).
85. Canton R, Valdezate S, Vindel A et al. Antimicrobial susceptibility profile of molecular typed cystic fibrosis Stenotrophomonas maltophilia isolates and differences with noncystic fibrosis isolates. Pediatr. Pulmonol. 35(2), 99-107 (2003).
86. Krueger TS, Clark EA, Nix DE. In vitro susceptibility of Stenotrophomonas maltophilia to various antimicrobial combinations. Diagn. Microbiol. Infect. Dis. 41(1-2), 71-78 (2001).
87. Saiman L, Chen Y, Gabriel PS, Knirsch C. Synergistic activities of macrolide antibiotics against Pseudomonas aeruginosa, Burkholderia cepacia, Stenotrophomonas maltophilia, and Alcaligenes xylosoxidans isolated from patients with cystic fibrosis. Antimicrob. Agents Chemother. 46(4), 1105-1107 (2002).
88. Saiman L, Marshall BC, Mayer-Hamblett N et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 290(13), 1749-1756 (2003).
89. Jevons MP, Coe AW, Parker MT. Methicillin resistance in staphylococci. Lancet 1, 904-907 (1963).
90. Haddadin AS, Fappiano SA, Lipsett PA. Methicillin resistant Staphylococcus aureus (MRSA) in the intensive care unit. Postgrad. Med. J. 78(921), 385-392 (2002).
91. Methicillin-resistant Staphylococcus aureus in French hospitals: a 2-month survey in 43 hospitals, 1995. The Hopital Propre II Study Group. Infect. Control. Hosp. Epidemiol. 20(7), 478-486 (1999).
92. Dziekan G, Hahn A, Thune K et al. Methicillin-resistant Staphylococcus aureus in a teaching hospital: investigation of nosocomial transmission using a matched case-control study. J. Hosp. Infect. 46(4), 263-270 (2000).
93. Deresinski S. Methicillin-resistant Staphylococcus aureus: an evolutionary, epidemiologic, and therapeutic odyssey. Clin. Infect. Dis. 40(4), 562-573 (2005).
94. Gonzalez-Zorn B, Senna JP, Fiette L et al. Bacterial and host factors implicated in nasal carriage of methicillin-resistant Staphylococcus aureus in mice. Infect. Immun. 73(3), 1847-1851 (2005).
95. Nadesalingam K, Conway SP, Denton M. Risk factors for acquisition of methicillin-resistant Staphylococcus aureus (MRSA) by patients with cystic fibrosis. J. Cyst. Fibros. 4(1), 49-52 (2005).
96. Graffunder EM, Venezia RA. Risk factors associated with nosocomial methicillin-resistant Staphylococcus aureus (MRSA) infection including previous use of antimicrobials. J. Antimicrob. Chemother. 49(6), 999-1005 (2002).
97. Tumbarello M, de Gaetano Donati K, Tacconelli E et al. Risk factors and predictors of mortality of methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia in HIV-infected patients. J. Antimicrob. Chemother. 50(3), 375-382 (2002).
98. von Baum H, Schmidt C, Svoboda D, Bock-Hensley O, Wendt C. Risk factors for methicillin-resistant Staphylococcus aureus carriage in residents of German nursing homes. Infect. Control. Hosp. Epidemiol. 23(9), 511-515 (2002).
99. Boyle M, Ross T, Goldberg JD et al. Molecular epidemiology of MRSA infection in cystic fibrosis and its clinical implications. In: North American Cystic Fibrosis Conference. Pediatric Pulmonology, MD, USA, (2005)
100. Miall LS, McGinley NT, Brownlee KG, Conway SP. Methicillin resistant Staphylococcus aureus (MRSA) infection in cystic fibrosis. Arch. Dis. Child. 84(2), 160-162 (2001).
101. Thomas SR, Gyi KM, Gaya H, Hodson ME. Methicillin-resistant Staphylococcus aureus: impact at a national cystic fibrosis centre. J. Hosp. Infect. 40(3), 203-209 (1998).
102. Maiz L, Canton R, Mir N, Baquero F, Escobar H. Aerosolized vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infection in cystic fibrosis. Pediatr. Pulmonol. 26(4), 287-289 (1998).
103. Ferrin M, Zuckerman JB, Meagher A, Blumberg EA. Successful treatment of methicillin-resistant Staphylococcus aureus pulmonary infection with linezolid in a patient with cystic fibrosis. Pediatr. Pulmonol. 33(3), 221-223 (2002).
104. Saralaya D, Peckham DG, Hulme B et al. Serum and sputum concentrations following the oral administration of linezolid in adult patients with cystic fibrosis. J. Antimicrob. Chemother. 53(2), 325-328 (2004).
105. Tsiodras S, Gold HS, Sakoulas G et al. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet 358(9277), 207-208 (2001).
106. Garske LA, Kidd TJ, Gan R et al. Rifampicin and sodium fusidate reduces the frequency of methicillin-resistant Staphylococcus aureus (MRSA) isolation in adults with cystic fibrosis and chronic MRSA infection. J. Hosp. Infect. 56(3), 208-214 (2004).
107. Solis A, Brown D, Hughes J, Van Saene HK, Heaf DP. Methicillin-resistant Staphylococcus aureus in children with cystic fibrosis: an eradication protocol. Pediatr. Pulmonol. 36(3), 189-195 (2003).
108. Spear JB, Fuhrer J, Kirby BD. Achromobacter xylosoxidans (Alcaligenes xylosoxidans subsp. xylosoxidans) bacteremia associated with a well-water source: case report and review of the literature. J. Clin. Microbiol. 26(3), 598-599 (1988).
109. Burns JL, Emerson J, Stapp JR et al. Microbiology of sputum from patients at cystic fibrosis centers in the United States. Clin. Infect. Dis. 27(1), 158-163 (1998).
110. Mandell WF, Garvey GJ, Neu HC. Achromobacter xylosoxidans bacteremia. Rev. Infect. Dis. 9(5), 1001-1005 (1987).
111. Moissenet D, Baculard A, Valcin M et al. Colonization by Alcaligenes xylosoxidans in children with cystic fibrosis: a retrospective clinical study conducted by means of molecular epidemiological investigation. Clin. Infect. Dis. 24(2), 274-275 (1997).
112. Romano L, Bellodi S, Lugani F, Manno G. To the editor: alcaligenes as a pathogen in airways chronic infection in cystic fibrosis. Pediatr. Pulmonol. 35(5), 412-413 (2003).
113. Tan K, Conway SP, Brownlee KG, Etherington C, Peckham DG. Alcaligenes infection in cystic fibrosis. Pediatr. Pulmonol. 34(2), 101-104 (2002).
114. Saiman L, Chen Y, Tabibi S et al. Identification and antimicrobial susceptibility of Alcaligenes xylosoxidans isolated from patients with cystic fibrosis. J. Clin. Microbiol. 39(11), 3942-3945 (2001).
115. Coenye T, Falsen E, Hoste B et al. Description of Pandoraea gen. nov. with Pandoraea apista sp. nov., Pandoraea pulmonicola sp. nov., Pandoraea pnomenusa sp. nov., Pandoraea sputorum sp. nov. and Pandoraea norimbergensis comb. nov. Int. J. Syst. Evol. Microbiol. 50(Pt 2), 887-899 (2000).
116. Stryjewski ME, LiPuma JJ, Messier RH Jr, Reller LB, Alexander BD. Sepsis, multiple organ failure, and death due to Pandoraea pnomenusa infection after lung transplantation. J. Clin. Microbiol. 41(5), 2255-2257 (2003).
117. Moore JE, Reid A, Millar BC et al. Pandoraea apista isolated from a patient with cystic fibrosis: problems associated with laboratory identification. Br. J. Biomed. Sci. 59(3), 164-166 (2002).
118. Coenye T, Liu L, Vandamme P, LiPuma JJ. Identification of Pandoraea species by 16S ribosomal DNA-based PCR assays. J. Clin. Microbiol. 39(12), 4452-4455 (2001).
119. Segonds C, Paute S, Chabanon G. Use of amplified ribosomal DNA restriction analysis for identification of Ralstonia and Pandoraea species: interest in determination of the respiratory bacterial flora in patients with cystic fibrosis. J. Clin. Microbiol. 41(7), 3415-3418 (2003).
120. Johnson LN, Han JY, Moskowitz SM et al. Pandoraea bacteremia in a cystic fibrosis patient with associated systemic illness. Pediatr. Infect. Dis. J. 23(9), 881-882 (2004).
121. Jorgensen IM, Johansen HK, Frederiksen B et al. Epidemic spread of Pandoraea apista, a new pathogen causing severe lung disease in cystic fibrosis patients. Pediatr. Pulmonol. 36(5), 439-446 (2003).
122. Diagnosis and treatment of disease caused by nontuberculous mycobacteria. This official statement of the American Thoracic Society was approved by the Board of Directors, March 1997. Medical Section of the American Lung Association. Am. J. Respir. Crit. Care Med. 156(2 Pt 2), S1-S25 (1997).
123. Olivier KN, Weber DJ, Wallace RJ Jr et al. Nontuberculous mycobacteria. I: multicenter prevalence study in cystic fibrosis. Am. J. Respir. Crit. Care Med. 167(6), 828-834 (2003).
124. Olivier KN, Weber DJ, Lee JH et al. Nontuberculous mycobacteria. II: nested-cohort study of impact on cystic fibrosis lung disease. Am. J. Respir. Crit. Care Med. 167(6), 835-840 (2003).
125. Saiman L, Siegel J. Infection control in cystic fibrosis. Clin. Microbiol. Rev. 17(1), 57-71 (2004).
126. Vonberg RP, Gastmeier P. Isolation of infectious cystic fibrosis patients: results of a systematic review. Infect. Control. Hosp. Epidemiol. 26(4), 401-419 (2005).
127. Zimakoff J, Hoiby N, Rosendal K, Guilbert JP. Epidemiology of Pseudomonas aeruginosa infection and the role of contamination of the environment in a cystic fibrosis clinic. J. Hosp. Infect. 4(1), 31-40 (1983).
128. Speert DP, Campbell ME. Hospital epidemiology of Pseudomonas aeruginosa from patients with cystic fibrosis. J. Hosp. Infect. 9(1), 11-21 (1987).
129. Bosshammer J, Fiedler B, Gudowius P et al. Comparative hygienic surveillance of contamination with pseudomonads in a cystic fibrosis ward over a 4-year period. J. Hosp. Infect. 31(4), 261-274 (1995).
130. Grothues D, Koopmann U, von der Hardt H, Tummler B. Genome fingerprinting of Pseudomonas aeruginosa indicates colonization of cystic fibrosis siblings with closely related strains. J. Clin. Microbiol. 26(10), 1973-1977 (1988).
131. Ojeniyi B, Frederiksen B, Hoiby N. Pseudomonas aeruginosa cross-infection among patients with cystic fibrosis during a winter camp. Pediatr. Pulmonol. 29(3), 177-181 (2000).
132. Jones AM, Govan JR, Doherty CJ et al. Spread of a multiresistant strain of Pseudomonas aeruginosa in an adult cystic fibrosis clinic. Lancet 358(9281), 557-558 (2001).
133. Pedersen SS, Koch C, Hoiby N, Rosendal K. An epidemic spread of multiresistant Pseudomonas aeruginosa in a cystic fibrosis centre. J. Antimicrob. Chemother. 17(4), 505-516 (1986).
134. Denton M, Kerr K, Mooney L et al. Transmission of colistin-resistant Pseudomonas aeruginosa between patients attending a pediatric cystic fibrosis center. Pediatr. Pulmonol. 34(4), 257-261 (2002).
135. Campana S, Taccetti G, Ravenni N et al. Molecular epidemiology of Pseudomonas aeruginosa, Burkholderia cepacia complex and methicillin-resistant Staphylococcus aureus in a cystic fibrosis center. J. Cyst. Fibros. 3(3), 159-163 (2004).
136. Pegues DA, Schidlow DV, Tablan OC et al. Possible nosocomial transmission of Pseudomonas cepacia in patients with cystic fibrosis. Arch. Pediatr. Adolesc. Med. 148(8), 805-812 (1994).
137. Burdge DR, Nakielna EM, Noble MA. Case-control and vector studies of nosocomial acquisition of Pseudomonas cepacia in adult patients with cystic fibrosis. Infect. Control. Hosp. Epidemiol. 14(3), 127-130 (1993).
138. Tablan OC, Chorba TL, Schidlow DV et al. Pseudomonas cepacia colonization in patients with cystic fibrosis: risk factors and clinical outcome. J. Pediatr. 107(3), 382-387 (1985).
139. Pegues DA, Carson LA, Tablan OC et al. Acquisition of Pseudomonas cepacia at summer camps for patients with cystic fibrosis. Summer Camp Study Group. J. Pediatr. 124(5 Pt 1), 694-702 (1994).
140. LiPuma JJ, Dasen SE, Nielson DW, Stern RC, Stull TL. Person-to-person transmission of Pseudomonas cepacia between patients with cystic fibrosis. Lancet 336(8723), 1094-1096 (1990).
141. Govan JR, Brown PH, Maddison J et al. Evidence for transmission of Pseudomonas cepacia by social contact in cystic fibrosis. Lancet 342(8862), 15-19 (1993).
142. Givney R, Vickery A, Holliday A, Pegler M, Benn R. Methicillin-resistant Staphylococcus aureus in a cystic fibrosis unit. J. Hosp. Infect. 35(1), 27-36 (1997).
143. Sheretz RJ, Reagan DR, Hampton KD et al. A cloud adult: the Staphylococcus aureus-virus interaction revisited. Ann. Intern. Med. 124(6), 539-547 (1996).
144. Schlichting C, Branger C, Fournier JM et al. Typing of Staphylococcus aureus by pulsed-field get electrophoresis, zymotyping, capsular typing, and phage typing: resolution of clonal relationships. J. Clin. Microbiol. 31(2), 227-232 (1993).
145. Salgado CD, Farr BM, Calfee DP. Community-acquired methicillin-resistant Staphylococcus aureus: a meta-analysis of prevalence and risk factors. Clin. Infect. Dis. 36(2), 131-139 (2003).
146. Doebbeling BN, Breneman DL, Neu HC et al. Elimination of Staphylococcus aureus nasal carriage in health care workers: analysis of six clinical trials with calcium mupirocin ointment. The Mupirocin Collaborative Study Group. Clin. Infect. Dis. 17(3), 466-474 (1993).
147. Krzewinski JW, Nguyen CD, Foster JM, Burns JL. Use of random amplified polymorphic DNA PCR to examine epidemiology of Stenotrophomonas maltophilia and Achromobacter (Alcaligenes) xylosoxidans from patients with cystic fibrosis. J. Clin. Microbiol. 39(10), 3597-3602 (2001).
148. Smyth A, Tan K H-V, Hyman-Taylor P et al. Once versus three-times daily regimens of tobramycin treatment for pulmonary exacerbations of cystic fibrosis- the TOPIC study: a randomised controlled trial. Lancet 365(9459), 573-578 (2005).